April 10, 2017 09:17 AM EDTUpdated 12:17 PM

The master dealmaker is back: David Hung takes the helm at Vivek Ramaswamy's Axovant

John Carroll

Editor & Founder

David Hung earned his spurs as a master dealmaker in biotech, blazing through a string of major partnerships for good (and bad) drugs before selling …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

The master dealmaker is back: David Hung takes the helm at Vivek Ramaswamy's Axovant

John Carroll

Editor & Founder

Sign up to read this article for free.

Regeneron buys London-based ocular biotech

A look at biotech's year of the megaround

Biopharma to raise more than 1,000 drug prices in 2025, advisory firm predicts

Roche circles back to China biotech with $80M deal for lung cancer ADC

Pennsylvania Blue Cross insurer restricts coverage of medicines granted FDA accelerated approval

Neumora's major depression drug flunks first of three Phase 3 trials

The mas­ter deal­mak­er is back: David Hung takes the helm at Vivek Ra­maswamy's Ax­o­vant

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Re­gen­eron buys Lon­don-based oc­u­lar biotech

A look at biotech's year of the megaround

Bio­phar­ma to raise more than 1,000 drug prices in 2025, ad­vi­so­ry firm pre­dicts

Roche cir­cles back to Chi­na biotech with $80M deal for lung can­cer ADC

Penn­syl­va­nia Blue Cross in­sur­er re­stricts cov­er­age of med­i­cines grant­ed FDA ac­cel­er­at­ed ap­proval

Neu­mora's ma­jor de­pres­sion drug flunks first of three Phase 3 tri­als

The master dealmaker is back: David Hung takes the helm at Vivek Ramaswamy's Axovant

Regeneron buys London-based ocular biotech

Biopharma to raise more than 1,000 drug prices in 2025, advisory firm predicts

Roche circles back to China biotech with $80M deal for lung cancer ADC

Pennsylvania Blue Cross insurer restricts coverage of medicines granted FDA accelerated approval

Neumora's major depression drug flunks first of three Phase 3 trials